Research
Hormonal
GLP-1 Receptor Agonists (GLP-1 RA) and SGLT-2 Inhibitors (SGLT-2i) provide significant cardiovascular and renal benefits, with GLP-1 RAs also offering substantial weight loss and HbA1c reduction.
Consider GLP-1 RAs or SGLT-2 inhibitors if you need better blood sugar control, weight loss, or heart protection. These drugs have strong evidence for reducing heart attacks and strokes. Be aware of potential stomach issues, which often improve over time.
StrongSupportsVERY_HIGH confidence
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) offer notable benefits for HbA1c and weight reduction, with significant cardiovascular benefits. Sodium-glucose cotransporter inhibitors (SGLT-2i) lower glucose levels independently of insulin while conferring notable benefits for cardiovascular, renal, and heart-failure outcomes.
Why this rating
Supported by multiple large-scale clinical trials (SELECT, SAVOR, EMPA-REG, etc.) and meta-analyses.
Source
Drug Therapies for Diabetes
Roni Weinberg Sibony et al. · International Journal of Molecular Sciences · 2023
narrative_reviewCited 97×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →